Pfizer Says 2nd Circ. Can't Review Lipitor FCA Suit
Pfizer Inc. told the Second Circuit on Monday it lacks jurisdiction to review a False Claims Act dispute over alleged off-label marketing of the company's cholesterol drug Lipitor, arguing that a...To view the full article, register now.
Already a subscriber? Click here to view full article